Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-11
2008-03-11
Habte, Kahsay (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S187000, C544S335000, C514S318000, C514S326000
Reexamination Certificate
active
10787775
ABSTRACT:
Arylpiperazines of formula (I) useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13
REFERENCES:
patent: 5998412 (1999-12-01), Broka et al.
patent: 6100266 (2000-08-01), Montana et al.
patent: 6130220 (2000-10-01), Broka et al.
patent: 6143744 (2000-11-01), Broka et al.
patent: 6235786 (2001-05-01), Dai et al.
patent: 6294573 (2001-09-01), Curtin et al.
patent: 6376506 (2002-04-01), Broka et al.
patent: 6479502 (2002-11-01), Martin
patent: 6482827 (2002-11-01), Alpegiani
patent: 2003/0050310 (2003-03-01), Martin
patent: 198 02 350 (1998-07-01), None
patent: WO-98/16514 (1998-04-01), None
patent: WO-99/02510 (1999-01-01), None
patent: WO-99/38843 (1999-08-01), None
Coussens et al. {SCIENCE, vol. 295, Mar. 29, 2002}.
Barlaam Bernard Christophe
Newcombe Nicholas John
Tucker Howard
Waterson David
AstraZeneca AB
Habte Kahsay
Ropes & Gray LLP
LandOfFree
Arylpiperazines and their use as metalloproteinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Arylpiperazines and their use as metalloproteinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylpiperazines and their use as metalloproteinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3910213